GSK3B and Parkinson disease: Inhibition of GSK-3β was shown to protect dopaminergic neurons in various neurotoxic models of PD (Petit-Paitel et al., 2009; Li et al., 2014) and is a target of ongoing drug development efforts (Przewodowska et al., 2021).